These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

174 related items for PubMed ID: 21571767

  • 1. Low-dose rituximab therapy for refractory thrombocytopenia in patients with systemic lupus erythematosus--a prospective pilot study.
    Chen H, Zheng W, Su J, Xu D, Wang Q, Leng X, Zhang W, Li M, Tang F, Zhang X, Zeng X, Zhao Y, Zhang F.
    Rheumatology (Oxford); 2011 Sep; 50(9):1640-4. PubMed ID: 21571767
    [Abstract] [Full Text] [Related]

  • 2. Intensive short-term treatment with rituximab, cyclophosphamide and methylprednisolone pulses induces remission in severe cases of SLE with nephritis and avoids further immunosuppressive maintenance therapy.
    Roccatello D, Sciascia S, Rossi D, Alpa M, Naretto C, Baldovino S, Menegatti E, La Grotta R, Modena V.
    Nephrol Dial Transplant; 2011 Dec; 26(12):3987-92. PubMed ID: 21385860
    [Abstract] [Full Text] [Related]

  • 3. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with rituximab.
    Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, Tanaka Y.
    Rheumatology (Oxford); 2005 Feb; 44(2):176-82. PubMed ID: 15494350
    [Abstract] [Full Text] [Related]

  • 4. Anti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.
    Jovancevic B, Lindholm C, Pullerits R.
    Lupus; 2013 Jun; 22(7):664-74. PubMed ID: 23612795
    [Abstract] [Full Text] [Related]

  • 5. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC, Wang W, Zhou YH, Wang XM, Wang X, Wang YL, Sun GZ, Hou M.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [Abstract] [Full Text] [Related]

  • 6. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus.
    Albert D, Dunham J, Khan S, Stansberry J, Kolasinski S, Tsai D, Pullman-Mooar S, Barnack F, Striebich C, Looney RJ, Prak ET, Kimberly R, Zhang Y, Eisenberg R.
    Ann Rheum Dis; 2008 Dec; 67(12):1724-31. PubMed ID: 18250115
    [Abstract] [Full Text] [Related]

  • 7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P, Bjerrum OW, Nielsen OJ, Jensen BA, Clausen NT, Hansen PB, Andersen I, Schmidt K, Andersen TM, Peterslund NA, Birgens HS, Plesner T, Pedersen BB, Hasselbalch HC.
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [Abstract] [Full Text] [Related]

  • 8. B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus.
    Kumar S, Benseler SM, Kirby-Allen M, Silverman ED.
    Pediatrics; 2009 Jan; 123(1):e159-63. PubMed ID: 19074962
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and Safety of Rituximab in Systemic Lupus Erythematosus and Sjögren Syndrome Patients With Refractory Thrombocytopenia: A Retrospective Study of 21 Cases.
    Jiang B, Li T, Guo L, Shen H, Ye S, Chen S.
    J Clin Rheumatol; 2015 Aug; 21(5):244-50. PubMed ID: 26203828
    [Abstract] [Full Text] [Related]

  • 10. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus.
    Marks SD, Patey S, Brogan PA, Hasson N, Pilkington C, Woo P, Tullus K.
    Arthritis Rheum; 2005 Oct; 52(10):3168-74. PubMed ID: 16200620
    [Abstract] [Full Text] [Related]

  • 11. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias.
    Rao A, Kelly M, Musselman M, Ramadas J, Wilson D, Grossman W, Shenoy S.
    Pediatr Blood Cancer; 2008 Apr; 50(4):822-5. PubMed ID: 17570702
    [Abstract] [Full Text] [Related]

  • 12. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
    Li Y, Wang XM, Mao M, Zhang XY, Fu L, Ai HM, Zhang LX.
    Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
    [Abstract] [Full Text] [Related]

  • 13. Rituximab therapy for childhood-onset systemic lupus erythematosus.
    Willems M, Haddad E, Niaudet P, Koné-Paut I, Bensman A, Cochat P, Deschênes G, Fakhouri F, Leblanc T, Llanas B, Loirat C, Pillet P, Ranchin B, Salomon R, Ulinski T, Bader-Meunier B, French Pediatric-Onset SLE Study Group.
    J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
    [Abstract] [Full Text] [Related]

  • 14. [Efficacy and safety of two different low-dose rituximab regimens for Chinese adult patients with immune thrombocytopenia].
    Sui T, Zhang L, Zhou ZP, Xue F, Ge J, Yang RC.
    Zhonghua Xue Ye Xue Za Zhi; 2011 Sep; 32(9):583-6. PubMed ID: 22338149
    [Abstract] [Full Text] [Related]

  • 15. Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: a longitudinal analysis of 52 Hispanic patients.
    Garcia-Carrasco M, Mendoza-Pinto C, Sandoval-Cruz M, Soto-Vega E, Beltran-Castillo A, Jimenez-Hernandez M, Graillet D, Gonzalez L, Rojas-Rodriguez J, Pineda-Almazana A, Zamudio-Huerta L, Lopez-Colombo A.
    Lupus; 2010 Feb; 19(2):213-9. PubMed ID: 19965944
    [Abstract] [Full Text] [Related]

  • 16. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab.
    Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, Sloand JA, Rosenblatt J, Sanz I.
    Arthritis Rheum; 2004 Aug; 50(8):2580-9. PubMed ID: 15334472
    [Abstract] [Full Text] [Related]

  • 17. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus.
    Lindholm C, Börjesson-Asp K, Zendjanchi K, Sundqvist AC, Tarkowski A, Bokarewa M.
    J Rheumatol; 2008 May; 35(5):826-33. PubMed ID: 18398943
    [Abstract] [Full Text] [Related]

  • 18. Low-dose rituximab is effective in pemphigus.
    Horváth B, Huizinga J, Pas HH, Mulder AB, Jonkman MF.
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [Abstract] [Full Text] [Related]

  • 19. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
    Conti F, Ceccarelli F, Perricone C, Alessandri C, Conti V, Massaro L, Truglia S, Spinelli FR, Spadaro A, Valesini G.
    Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
    [Abstract] [Full Text] [Related]

  • 20. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
    Smith KG, Jones RB, Burns SM, Jayne DR.
    Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.